tiprankstipranks
Trending News
More News >
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
US Market

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Compare
659 Followers
See the Price Targets and Ratings of:

PTGX Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Protagonist
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PTGX Stock 12 Month Forecast

Average Price Target

$71.11
▲(53.16%Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $71.11 with a high forecast of $82.00 and a low forecast of $61.00. The average price target represents a 53.16% change from the last price of $46.43.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","83":"$83","38.75":"$38.8","53.5":"$53.5","68.25":"$68.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$61.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,38.75,53.5,68.25,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.99,47.83692307692308,50.683846153846154,53.53076923076923,56.37769230769231,59.22461538461538,62.071538461538466,64.91846153846154,67.76538461538462,70.6123076923077,73.45923076923077,76.30615384615385,79.15307692307692,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.99,46.99923076923077,49.00846153846154,51.01769230769231,53.026923076923076,55.036153846153844,57.04538461538462,59.05461538461539,61.06384615384616,63.073076923076925,65.0823076923077,67.09153846153846,69.10076923076923,{"y":71.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,44.99,46.221538461538465,47.45307692307693,48.684615384615384,49.91615384615385,51.14769230769231,52.37923076923077,53.610769230769236,54.84230769230769,56.073846153846155,57.30538461538462,58.536923076923074,59.76846153846154,{"y":61,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.56,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.2,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$82.00Average Price Target$71.11Lowest Price Target$61.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PTGX
TipRanks AITipRanks
Not Ranked
TipRanks
$44
Hold
-5.23%
Downside
Reiterated
05/16/25
Protagonist Therapeutics' overall score reflects its financial performance and technical analysis. While the company has shown signs of improved cost management and cash flow, the lack of revenue growth and high valuation are significant concerns. Technical indicators suggest moderate market sentiment without strong momentum. Investors should be cautious of the high P/E ratio and assess the company's ability to stabilize revenue.
H.C. Wainwright Analyst forecast on PTGX
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$80
Buy
72.30%
Upside
Reiterated
05/19/25
Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
Wedbush Analyst forecast on PTGX
Yun ZhongWedbush
Wedbush
$70
Buy
50.76%
Upside
Reiterated
05/07/25
Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships
TD Cowen
$65
Buy
40.00%
Upside
Reiterated
05/06/25
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
BTIG
$82
Buy
76.61%
Upside
Reiterated
04/10/25
Protagonist Therapeutics' Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects
Jefferies Analyst forecast on PTGX
Roger SongJefferies
Jefferies
$68
Buy
46.46%
Upside
Reiterated
04/10/25
Promising Potential of Protagonist Therapeutics' Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song
J.P. Morgan Analyst forecast on PTGX
Brian ChengJ.P. Morgan
J.P. Morgan
$57$66
Buy
42.15%
Upside
Reiterated
03/12/25
J.P. Morgan Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
BMO Capital Analyst forecast on PTGX
Evan SeigermanBMO Capital
BMO Capital
$62$72
Buy
55.07%
Upside
Reiterated
03/11/25
Protagonist Therapeutics price target raised to $72 from $62 at BMO CapitalProtagonist Therapeutics price target raised to $72 from $62 at BMO Capital
Truist Financial Analyst forecast on PTGX
Srikripa DevarakondaTruist Financial
Truist Financial
$60$76
Buy
63.69%
Upside
Reiterated
03/11/25
Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial
Citizens JMP Analyst forecast on PTGX
Jonathan WollebenCitizens JMP
Citizens JMP
$61
Buy
31.38%
Upside
Reiterated
03/10/25
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of IcotrokinraWe think icotrokinra is likely to be approved (90% POS) and we model peak sales of >$5B, which is in line with JNJ’s projections (our coverage here).
Goldman Sachs Analyst forecast on PTGX
Richard Law CFAGoldman Sachs
Goldman Sachs
$43$38
Hold
-18.16%
Downside
Reiterated
02/24/25
Protagonist Therapeutics (PTGX) PT Lowered to $38 at Goldman SachsGoldman Sachs lowered its price target on Protagonist Therapeutics (NASDAQ: PTGX) to $38.00 (from $43.00) while maintaining a Neutral rating.
Capital One Financial Analyst forecast on PTGX
Tim ChiangCapital One Financial
Capital One Financial
$48
Buy
3.38%
Upside
Assigned
08/06/24
Protagonist Therapeutics Receives 'Buy' Rating on Strong Performance and Promising Pipeline
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on PTGX
TipRanks AITipRanks
Not Ranked
TipRanks
$44
Hold
-5.23%
Downside
Reiterated
05/16/25
Protagonist Therapeutics' overall score reflects its financial performance and technical analysis. While the company has shown signs of improved cost management and cash flow, the lack of revenue growth and high valuation are significant concerns. Technical indicators suggest moderate market sentiment without strong momentum. Investors should be cautious of the high P/E ratio and assess the company's ability to stabilize revenue.
H.C. Wainwright Analyst forecast on PTGX
Douglas TsaoH.C. Wainwright
H.C. Wainwright
$80
Buy
72.30%
Upside
Reiterated
05/19/25
Protagonist Therapeutics: Strategic Partnerships and Innovative Therapies Drive Buy Rating
Wedbush Analyst forecast on PTGX
Yun ZhongWedbush
Wedbush
$70
Buy
50.76%
Upside
Reiterated
05/07/25
Protagonist Therapeutics: Promising Future with Strong Clinical Data and Strategic Partnerships
TD Cowen
$65
Buy
40.00%
Upside
Reiterated
05/06/25
Protagonist Therapeutics: Buy Rating Backed by Promising Clinical Trials and Market Opportunities
BTIG
$82
Buy
76.61%
Upside
Reiterated
04/10/25
Protagonist Therapeutics' Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects
Jefferies Analyst forecast on PTGX
Roger SongJefferies
Jefferies
$68
Buy
46.46%
Upside
Reiterated
04/10/25
Promising Potential of Protagonist Therapeutics' Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song
J.P. Morgan Analyst forecast on PTGX
Brian ChengJ.P. Morgan
J.P. Morgan
$57$66
Buy
42.15%
Upside
Reiterated
03/12/25
J.P. Morgan Reaffirms Their Buy Rating on Protagonist Therapeutics (PTGX)
BMO Capital Analyst forecast on PTGX
Evan SeigermanBMO Capital
BMO Capital
$62$72
Buy
55.07%
Upside
Reiterated
03/11/25
Protagonist Therapeutics price target raised to $72 from $62 at BMO CapitalProtagonist Therapeutics price target raised to $72 from $62 at BMO Capital
Truist Financial Analyst forecast on PTGX
Srikripa DevarakondaTruist Financial
Truist Financial
$60$76
Buy
63.69%
Upside
Reiterated
03/11/25
Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial
Citizens JMP Analyst forecast on PTGX
Jonathan WollebenCitizens JMP
Citizens JMP
$61
Buy
31.38%
Upside
Reiterated
03/10/25
Protagonist Therapeutics: Buy Rating Backed by Promising Phase 3 Results and Market Potential of IcotrokinraWe think icotrokinra is likely to be approved (90% POS) and we model peak sales of >$5B, which is in line with JNJ’s projections (our coverage here).
Goldman Sachs Analyst forecast on PTGX
Richard Law CFAGoldman Sachs
Goldman Sachs
$43$38
Hold
-18.16%
Downside
Reiterated
02/24/25
Protagonist Therapeutics (PTGX) PT Lowered to $38 at Goldman SachsGoldman Sachs lowered its price target on Protagonist Therapeutics (NASDAQ: PTGX) to $38.00 (from $43.00) while maintaining a Neutral rating.
Capital One Financial Analyst forecast on PTGX
Tim ChiangCapital One Financial
Capital One Financial
$48
Buy
3.38%
Upside
Assigned
08/06/24
Protagonist Therapeutics Receives 'Buy' Rating on Strong Performance and Promising Pipeline
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

1 Month
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+11.68%
assigned a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 76.92% of your transactions generating a profit, with an average return of +11.68% per trade.
3 Months
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+17.17%
assigned a xxx
rating 10 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +17.17% per trade.
1 Year
Jonathan WollebenCitizens JMP
Success Rate
21/21 ratings generated profit
100%
Average Return
+73.31%
reiterated a buy rating 3 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +73.31% per trade.
2 Years
xxx
Success Rate
21/21 ratings generated profit
100%
Average Return
+138.42%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +138.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTGX Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
4
8
13
16
14
Buy
17
15
19
19
11
Hold
2
2
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
25
33
36
25
In the current month, PTGX has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PTGX average Analyst price target in the past 3 months is 71.11.
Each month's total comprises the sum of three months' worth of ratings.

PTGX Financial Forecast

PTGX Earnings Forecast

The previous quarter’s earnings for PTGX were -$0.18.
The previous quarter’s earnings for PTGX were -$0.18.

PTGX Sales Forecast

The previous quarter’s earnings for PTGX were $28.32M.
The previous quarter’s earnings for PTGX were $28.32M.

PTGX Stock Forecast FAQ

What is PTGX’s average 12-month price target, according to analysts?
Based on analyst ratings, Protagonist Therapeutics’s 12-month average price target is 71.11.
    What is PTGX’s upside potential, based on the analysts’ average price target?
    Protagonist Therapeutics has 53.16% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PTGX a Buy, Sell or Hold?
          Protagonist Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Protagonist Therapeutics’s price target?
            The average price target for Protagonist Therapeutics is 71.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $82.00 ,the lowest forecast is $61.00. The average price target represents 53.16% Increase from the current price of $46.43.
              What do analysts say about Protagonist Therapeutics?
              Protagonist Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of PTGX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis